Real-world treatment patterns in patients with BRCA 1/2-positive (BRCA+) metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.
- Resource Type
- Article
- Source
- Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p52-52, 235p
- Subject
- Language
- ISSN
- 0732183X